Cytune Pharma's Corporate Minority - II Round

Cytune Pharma raised a round of funding on June 29, 2016.

Cytune Pharma is developing a portfolio of immunotherapeutic agents to treat primarily cancer. Cytune's advanced compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector.…

Articles about Cytune Pharma's Corporate Minority - II Round: